Kidney Transplant Rejection Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Key Companies - Veloxis Pharmaceuticals, Inc., Eledon Pharmaceuticals, Inc., Sangam

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Kidney Transplant Rejection pipeline constitutes 15+ key companies continuously working towards developing 15+ Kidney Transplant Rejection treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Kidney Transplant Rejection Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Kidney Transplant Rejection Market.

The Kidney Transplant Rejection Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Kidney Transplant Rejection Pipeline Report: https://www.delveinsight.com/report-store/kidney-transplant-rejection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Kidney Transplant Rejection treatment therapies with a considerable amount of success over the years.
• Kidney Transplant Rejection companies working in the treatment market are Veloxis Pharmaceuticals, Inc., Eledon Pharmaceuticals, Inc., Sangamo Therapeutics, Horizon Therapeutics Plc, CSL Behring, Medeor Therapeutics, Inc., and others, are developing therapies for the Kidney Transplant Rejection treatment
• Emerging Kidney Transplant Rejection therapies such as - VEL-101, Tegoprubart, TX200, Dazodalibep, Clazakizumab, MDR-101, and others are expected to have a significant impact on the Kidney Transplant Rejection market in the coming years.
• In order to show the effectiveness and safety of cellular immunotherapy with MDR-101 for inducing functional immunological tolerance in recipients of living donor kidney transplants, Medeor Therapeutics started an interventional phase III trial.

Kidney Transplant Rejection Overview
Kidney transplant rejection is an allogeneic immune reaction that degrades the graft's function and causes graft destruction. Patients who do not take their medicine as directed or who have insufficient immunosuppression frequently experience it. Chronic active antibody-mediated rejection (ABMR) and chronic active T cell-mediated rejection (TCMR) are the two main subtypes of kidney transplant rejection.

Get a Free Sample PDF Report to know more about Kidney Transplant Rejection Pipeline Therapeutic Assessment-
https://www.delveinsight.com/sample-request/kidney-transplant-rejection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Kidney Transplant Rejection Drugs Under Different Phases of Clinical Development Include:
• VEL-101: Veloxis Pharmaceuticals, Inc.
• Clazakizumab: CSL Behring
• Tegoprubart: Eledon Pharmaceuticals, Inc.
• TX200: Sangamo Therapeutics
• Dazodalibep: Horizon Therapeutics Plc
• MDR-101: Medeor Therapeutics, Inc.

Route of Administration
Kidney Transplant Rejection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
• Molecule Type

Molecule Type
Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Kidney Transplant Rejection Pipeline Therapeutics Assessment
• Kidney Transplant Rejection Assessment by Product Type
• Kidney Transplant Rejection By Stage and Product Type
• Kidney Transplant Rejection Assessment by Route of Administration
• Kidney Transplant Rejection By Stage and Route of Administration
• Kidney Transplant Rejection Assessment by Molecule Type
• Kidney Transplant Rejection by Stage and Molecule Type

DelveInsight's Kidney Transplant Rejection Report covers around 15+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Kidney Transplant Rejection product details are provided in the report. Download the Kidney Transplant Rejection pipeline report to learn more about the emerging Kidney Transplant Rejection therapies at:
https://www.delveinsight.com/sample-request/kidney-transplant-rejection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Kidney Transplant Rejection Therapeutics Market include:
Key companies developing therapies for Kidney Transplant Rejection are - Alphamab Oncology, AltruBio Inc, Amgen Inc, Amyndas Pharmaceuticals LLC, Astellas Pharma Inc, Bristol-Myers Squibb Co, Cynata Therapeutics Ltd, Eledon Pharmaceuticals Inc, Enceladus Pharmaceuticals BV, Hansa Biopharma AB, Helocyte Bi, and others.

Kidney Transplant Rejection Pipeline Analysis:
The Kidney Transplant Rejection pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Kidney Transplant Rejection with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Kidney Transplant Rejection Treatment.
• Kidney Transplant Rejection key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Kidney Transplant Rejection Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Kidney Transplant Rejection market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Kidney Transplant Rejection drugs and therapies-
https://www.delveinsight.com/sample-request/kidney-transplant-rejection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Kidney Transplant Rejection Pipeline Market Drivers
• Rising Prevalence of chronic kidney diseases, increasing Number of Kidney Transplantations are some of the important factors that are fueling the Kidney Transplant Rejection Market.

Kidney Transplant Rejection Pipeline Market Barriers
• However, lack of donor and knowledge, long waiting time for transplantation and other factors are creating obstacles in the Kidney Transplant Rejection Market growth.

Scope of Kidney Transplant Rejection Pipeline Drug Insight
• Coverage: Global
• Key Kidney Transplant Rejection Companies: Veloxis Pharmaceuticals, Inc., Eledon Pharmaceuticals, Inc., Sangamo Therapeutics, Horizon Therapeutics Plc, CSL Behring, Medeor Therapeutics, Inc., and others
• Key Kidney Transplant Rejection Therapies: VEL-101, Tegoprubart, TX200, Dazodalibep, Clazakizumab, MDR-101, and others
• Kidney Transplant Rejection Therapeutic Assessment: Kidney Transplant Rejection current marketed and Kidney Transplant Rejection emerging therapies
• Kidney Transplant Rejection Market Dynamics: Kidney Transplant Rejection market drivers and Kidney Transplant Rejection market barriers

Request for Sample PDF Report for Kidney Transplant Rejection Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/kidney-transplant-rejection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Kidney Transplant Rejection Report Introduction
2 Kidney Transplant Rejection Executive Summary
3 Kidney Transplant Rejection Overview
4 Kidney Transplant Rejection- Analytical Perspective In-depth Commercial Assessment
5 Kidney Transplant Rejection Pipeline Therapeutics
6 Kidney Transplant Rejection Late Stage Products (Phase II/III)
7 Kidney Transplant Rejection Mid Stage Products (Phase II)
8 Kidney Transplant Rejection Early Stage Products (Phase I)
9 Kidney Transplant Rejection Preclinical Stage Products
10 Kidney Transplant Rejection Therapeutics Assessment
11 Kidney Transplant Rejection Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Kidney Transplant Rejection Key Companies
14 Kidney Transplant Rejection Key Products
15 Kidney Transplant Rejection Unmet Needs
16 Kidney Transplant Rejection Market Drivers and Barriers
17 Kidney Transplant Rejection Future Perspectives and Conclusion
18 Kidney Transplant Rejection Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Related Reports:

Kidney Transplant Rejection Market https://www.delveinsight.com/report-store/kidney-transplant-rejection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Kidney Transplant Rejection-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Kidney Transplant Rejection Epidemiology https://www.delveinsight.com/report-store/kidney-transplant-rejection-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Kidney Transplant Rejection Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Scedosporium Infection Market https://www.delveinsight.com/report-store/scedosporium-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Scedosporium Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Scedosporium Infection, historical and forecasted epidemiology as well as the Scedosporium Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Vascular Graft Devices Market https://www.delveinsight.com/report-store/vascular-grafts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2027 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Vascular Stents Market https://www.delveinsight.com/report-store/vascular-stents-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2027 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Bladder Scanners Market https://www.delveinsight.com/report-store/bladder-scanners-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Latest Reports By DelveInsight

Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast-by 2035 | Glioblastoma Market

To know more about our Consulting Services, Click here: DelveInsight Healthcare Consulting
Recent Blog's By DelveInsight:

• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
• Emerging Role of Digital Health in the Field of Oncology
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
• How are Technological Trends and Innovations Reshaping the Dementia Care
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry

Contact Us:

Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.